The Form 4 filing, an SEC report of insider stock trades, was submitted on Nov. 18, 2026. It reports trades from the day before and identifies Christophe Jean as a director of Rhythm Pharmaceuticals (RYTM).
Transaction details
| Transaction | |
|---|---|
| Date of Earliest Transaction | 2026-11-17 |
| Date of Latest Transaction | 2026-11-17 |
| Buy/Sell | sell |
| Transaction Count | 3 |
| Shares Transacted | 10,000 |
| Price | $109.66 |
| Total Transaction Value | $1,096,550.00 |
| Insider | |
| Ticker Symbol | RYTM |
| Company | RHYTHM PHARMACEUTICALS, INC. |
| Insider Name | JEAN CHRISTOPHE |
| Insider Title | Director |
| Sector - Industry | Healthcare - Biotechnology |
| Holdings | |
| Total Shares Owned After Transaction | 11,712 |
| Position Size Change | 46.06% |
| Filing | |
| Filing Date | 2026-11-18 |
| SEC Link | View filing |
FAQ
What type of transaction is this?
These were share sales, reported with transaction code S. The activity consists of three transactions in a single filing.
What was the average price of the transaction?
The average sale price was $109.655 per share, or $109.66 rounded to cents. This average covers the three reported sales. Separate prices for each sale were not provided.
How did this transaction affect the insider's holdings?
He sold 10,000 shares and reported owning 11,712 shares afterward. The shares sold made up 46.06% of his reported shares owned before the sales.
What's the total transaction value?
The total value of all three reported sales was $1,096,550.00. That amount covers the full 10,000 shares sold.
Are there any special circumstances around this transaction?
The record notes a Rule 10b5-1 trading-plan reference. These plans set trading instructions in advance. The available details do not confirm which of the three sales the reference covers.
Footnote text and plan terms were not provided. The date the plan was set up and its trading schedule remain unknown. The reference alone does not show whether the rule's legal requirements were met.
For research purposes only; not investment advice.